Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Head & Neck 1Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 89pembrolizumab 83Magnetic Resonance Spectroscopy 47Radiotherapy, Intensity-Modulated 41Specimen Handling 37Cetuximab 37Carboplatin 37Radiotherapy 36Nivolumab 29Paclitaxel 25Platinum 23Radiation 22Docetaxel 22Gemcitabine 21Biopsy 211,2-diaminocyclohexaneplatinum II citrate 21Surveys and Questionnaires 17Fluorouracil 14toripalimab 13Standard of Care 13Taxes 11Cyclophosphamide 10cemiplimab 9atezolizumab 9X-Rays 9Surgical Procedures, Operative 9Ipilimumab 9Immunoglobulin G 9Drug Therapy 9Capecitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Losartan × Head & Neck × 90 days × Clear all
NCT06211335 2026-03-12

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

University of California, Davis

Phase 1 Recruiting
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡